XORTX Therapeutics Inc. unveils investor presentation on XRx-026 for gout and kidney disease pipeline
I'm PortAI, I can summarize articles.
XORTX Therapeutics Inc. has updated its clinical and regulatory progress for XRx-026, targeting gout, highlighting successful trials and plans for a New Drug Application in 2026. The company is also advancing XRx-008 for kidney disease, with registration trials planned. The presentation details their technology, pipeline, and milestones.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments